Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome
Go back to Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome| PROSENSA HOLD (NASDAQ: RNA) | Delayed: 11.91 -0.26 (2.14%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $12.17 | 52 Week High | $22.80 | |||
| Open | $12.00 | 52 Week Low | $4.12 | |||
| Day High | $12.14 | P/E | N/A | |||
| Day Low | $11.78 | EPS | $0.00 | |||
| Volume | 101,292 | |||||
